Evidence map›Paper›PMID 27266421›Full record

ArticleThe Annals of thoracic surgery2016

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non-Small Cell Lung Cancer.

Matthew P Smeltzer, Nicholas Faris, Xinhua Yu, Robert A Ramirez, Laura E M Ramirez, Christopher G Wang, Courtney Adair, Allen Berry, Raymond U Osarogiagbon

Abstract readMulticenter Study
In one paragraph

Article in The Annals of thoracic surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected NSCLC in a High Mortality Area of the United States.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. [Gefitinib inhibits glycolysis and induces programmed cell death in non-small cell lung cancer cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  19. Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Matthew P SmeltzerDivision of Epidemiology, Biostatistics, and Environmental Health, University of Memphis School of Public Health, Memphis, Tennessee.
Nicholas FarisThoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee.
Xinhua YuDivision of Epidemiology, Biostatistics, and Environmental Health, University of Memphis School of Public Health, Memphis, Tennessee.
Robert A RamirezOchsner Medical Center, New Orleans, Louisiana.
Laura E M RamirezCrescent City Physicians, Inc, New Orleans, Louisiana.
Christopher G WangAlabama Oncology, Birmingham, Alabama.
Courtney AdairDuckworth Pathology Group, Memphis, Tennessee.
Allen BerryDepartment of Pathology, Saint Francis Hospital, Memphis, Tennessee.
Raymond U OsarogiagbonDivision of Epidemiology, Biostatistics, and Environmental Health, University of Memphis School of Public Health, Memphis, Tennessee; Thoracic Oncology Research Group, Baptist Cancer Center, Memphis, Tennessee. Electronic address: rosarogi@bmhcc.org.

Funding

Improving pathologic nodal staging of resected lung cancerR01CA172253 · NCI · UNIVERSITY OF MEMPHIS · PI OSAROGIAGBON, RAYMOND U · 2013 to 2022
$4.8M
NCI NIH HHS R01 CA172253
6 · The paper itself

Abstract

backgroundPathologic nodal stage is a key prognostic factor for patients with surgically resected lung cancer. We previously described the extent of missed intrapulmonary nodal metastasis in a cohort of patients treated at institutions in metropolitan Memphis, TN. With long-term follow-up, we now quantify the survival impact of missed nodal metastasis.

methodsWe conducted a prospective cohort study to evaluate inadvertently discarded lymph nodes in re-dissected remnant lung resection specimens from lung cancer patients. Retrieved material was histologically examined and classified as lymph nodes with and without metastasis. Survival information was obtained from hospital cancer registries. We plotted survival distributions with the use of the Kaplan-Meier method and evaluated them with proportional hazards models that controlled for important demographic and clinical factors.

resultsThe study included 110 patients who were 54% women and 69% white. Discarded lymph nodes with metastasis were found in 25 patients (23%). Patients with missed lymph node metastasis had an increased risk of death with an unadjusted hazard ratio of 2.0 (p = 0.06) and an adjusted hazard ratio of 1.4 (p = 0.45) compared with patients without missed lymph node metastasis. Patients with more than 2 missed lymph nodes with metastasis had 4.8 times the hazard of death (p = 0.0005) compared with patients without missed lymph node metastasis (adjusted hazard ratio 6.5, p = 0.0001).

conclusionsMetastasis to inadvertently discarded intrapulmonary lymph nodes from lung cancer resection specimens was associated with reduced survival. A more rigorous gross dissection protocol for lung cancer resection specimens may provide prognostically useful information.

Indexed as

Neoplasm StagingPneumonectomyRegistriesAgedCarcinoma, Non-Small-Cell LungFemaleFollow-Up StudiesHumansIncidenceLungLung NeoplasmsLymphatic MetastasisLymph Node ExcisionLymph NodesMaleMiddle Aged

Identifiers

PMID27266421
PMCPMC4958588

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.